GSK and Fiocruz Join for R&D and Greater Vaccine Access
GlaxoSmithKline has partnered with Brazil?s Oswaldo Cruz Foundation (Fiocruz) to develop and manufacture vaccines for pressing public health problems in Brazil.
GlaxoSmithKline plc (GSK, London, UK) has partnered with Brazil's Oswaldo Cruz Foundation (Fiocruz) to develop and manufacture vaccines for pressing public health problems in Brazil. The agreement will establish a new research and development collaboration program at Fiocruz to develop a vaccine for dengue fever.
GSK will also provide Fiocruz with access to the technology behind its 10-valent conjugate vaccine for pediatric pneumococcal disease, known as Synflorix. GSK will supply Synflorix to Fiocruz until the technology transfer is completed. The Brazilian government will incorporate the vaccine into its national immunization program in the coming months.
Synflorix was approved by Brazilian regulatory authorities on June 22. It is a 10-valent pneumococcal conjugate vaccine that protects against diseases such as pneumonia, meningitis, and bacteremia.
GSK Biologicals and Fiocruz initiated their first collaboration with an agreement to supply oral polio vaccines in 1985. Since then, GSK Biologicals and Fiocruz have formed several strategic alliances to provide Brazilians with key vaccines, including vaccines against Haemophilus influenzae type b (Hib), MMR (measles, mumps and rubella), and rotavirus. This is the partners’ first collaboration on an R&D center that will focus on the development of new vaccines.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
